Halberd Eradicates Another Inflammatory Cytokine, Interleukin-12, In Its Continuing Effort To Eliminate Neurodegenerative Diseases

Author's Avatar
Dec 15, 2021

JACKSON CENTER, PA / ACCESSWIRE / December 15, 2021 / Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-12 (IL-12) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Interleukin-12 is a pro-inflammatory cytokine which has recently been identified at elevated levels in patients with Alzheimer's Disease or mild cognitive impairment. Halberd's demonstrated ability to control the levels of IL-12, along with other inflammatory cytokines and antigens in CSF, is intended to slow or prevent the onset of Alzheimer's Disease and other cognitive decline. Currently, it is estimated that Alzheimer's Disease directly affects over 6 million people in the United States and over 40 million people worldwide.